Sutro Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. (STRO) on November 17, 2021, reporting events occurring on November 12, 2021. The Company is a biopharmaceutical firm incorporated in Delaware and listed on the Nasdaq Global Market.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the appointment of Heidi Hunter to the Board of Directors. Effective November 19, 2021, Ms. Hunter was appointed as a Class I director and assigned to the Audit Committee and the Science and Technology Committee.
Compensation and Governance Details
- Annual Retainers: Ms. Hunter will receive pro-rated portions of the following annual retainers for the remainder of 2021:
- $40,000 for Board service.
- $10,000 for Audit Committee service.
- $5,000 for Science and Technology Committee service.
- Stock Options: Two stock option grants were made effective November 19, 2021, with exercise prices based on the closing sale price on that date:
- 24,000 shares vesting monthly over three years.
- 9,884 shares vesting monthly until the 2022 annual meeting of shareholders.
- Indemnification: A standard indemnification agreement was executed, previously filed as Exhibit 10.1 to the Company's 2018 Form S-1.
Investor Verification Checklist
- Verify the closing stock price on November 19, 2021, to determine the exercise price of the granted options.
- Review the Company's existing compensation policy for non-employee directors to confirm the pro-rata calculation methodology.
- Confirm the vesting schedule details in the Company's next quarterly filing (Form 10-Q) or annual report (Form 10-K).
- Check for any subsequent filings regarding Ms. Hunter's continued service or changes to committee assignments.